Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518985 · ClinicalTrials.gov registry record · Phase 1
The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking
A Phase 1 study, sponsored by Stealth BioTherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01518985 is a Phase 1 study that has completed, run by Stealth BioTherapeutics. The registered enrollment target is 6 participants.
The verdict
NCT01518985, a Phase 1 study, has completed, sponsored by Stealth BioTherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This will be a phase 1 randomized, double-blind, 2-period, 2-sequence crossover trial enrolling 6 healthy volunteers to assess the impact of IV-administered Bendavia on the endothelial dysfunction induced by a single cigarette.
Interventions
- DRUG Bendavia
- DRUG Sterile saline (0.9%)
- OTHER Cigarette smoking
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01518985
The ClinicalTrials.gov registry entry for NCT01518985 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stealth BioTherapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bendavia is the first listed.
NCT01518985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01518985 about?
NCT01518985 is a clinical study titled "The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking". This will be a phase 1 randomized, double-blind, 2-period, 2-sequence crossover trial enrolling 6 healthy volunteers to assess the impact of IV-administered Bendavia on the endothelial dysfunction induced by a single cigarette.
What is the current status of trial NCT01518985?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-01. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01518985?
The interventions under investigation include: Bendavia (DRUG), Sterile saline (0.9%) (DRUG), Cigarette smoking (OTHER).
Who is sponsoring clinical trial NCT01518985?
This trial is sponsored by Stealth BioTherapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.